SCHEMBL1775627

SCHEMBL1775627

CCOC(=O)CCCOc1cc(-c2c(C#N)c(N)nc3sc(C(N)=O)c(N)c23)ccc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.74
HSP90AB1 P08238 1/20 0.63
MAPT P10636 5/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
NPSR1 Q6W5P4 4/20 0.51
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HPGD P15428 2/20 0.49
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
RXFP1 Q9HBX9 2/20 0.44
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
HTT P42858 1/20 0.42
ABCC1 P33527 2/20 0.42
ABCG2 Q9UNQ0 2/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776642 0.98 BRAF (0.73) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL1776425 0.97 BRAF (0.72) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL1776871 0.90 BRAF (0.79) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL1777095 0.88 BRAF (0.77) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL1777647 0.87 BRAF (0.76) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL429588 0.86 BRAF (1.00) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL12600461 0.85 BRAF (0.84) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL1776866 0.84 BRAF (0.79) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL18537731 0.83 BRAF (0.87) BRAFHSP90AB1MAPTMEN1KMT2A
SCHEMBL2287561 0.82 BRAF (0.89) BRAFHSP90AB1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943637-B2 Thienopyridine derivatives and the use thereof as HSP90 modulators MERCK PATENT GMBH (DE) 2011-05-17 US claimed
US-20090054452-A1 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2009-02-26 US claimed
EP-1853609-A1 THIENOPYRIDINE DERIVATIVES AND USE THEREOF AS HSP90 MODULATORS Merck Patent GmbH (DE) 2007-11-14 EP claimed
WO-2006092202-A1 THIENOPYRIDINE DERIVATIVES AND USE THEREOF AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-09-08 WO claimed
US-7943637-B2 Thienopyridine derivatives and the use thereof as HSP90 modulators MERCK PATENT GMBH (DE) 2011-05-17 US disclosed
US-7943637-B2 Thienopyridine derivatives and the use thereof as HSP90 modulators MERCK PATENT GMBH (DE) 2011-05-17 US disclosed
US-7943637-B2 Thienopyridine derivatives and the use thereof as HSP90 modulators MERCK PATENT GMBH (DE) 2011-05-17 US disclosed
US-20090054452-A1 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2009-02-26 US disclosed
US-20090054452-A1 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2009-02-26 US disclosed
US-20090054452-A1 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2009-02-26 US disclosed
EP-1853609-A1 THIENOPYRIDINE DERIVATIVES AND USE THEREOF AS HSP90 MODULATORS Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006092202-A1 THIENOPYRIDINE DERIVATIVES AND USE THEREOF AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054452-A1 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators HSP90AA1, HSP90AB1, HSP90AB2P BRAF 1646/4885HSP90AB1 2/4885MAPT 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.